<p><strong>優信有限公司</strong> (NASDAQ:UXIN) 的股票在經歷了一段動盪期後，最近一個月表現非常出色，漲幅達到 29%。並不是所有股東都會感到歡欣鼓舞，因為過去十二個月股價仍然下跌了令人失望的 25%。</p>
<p>在經歷如此大幅的價格跳升後，考慮到美國特種零售行業中幾乎一半的公司市銷率（&#34;P/S&#34;）低於 0.5 倍，你可能會認為優信的 1.8 倍市銷率並不值得研究。然而，市銷率可能因某種原因而偏高，需要進一步調查以確定其合理性。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>查看我們對優信的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974"/></p>
<p>NasdaqGS:UXIN 市銷率與行業比較 2025 年 12 月 31 日</p>
<h3>優信的市銷率對股東意味着什麼？</h3>
<p>優信最近的表現確實不錯，其收入增長超過了大多數其他公司。似乎許多人預計強勁的收入表現將持續，這提高了市銷率。然而，如果情況並非如此，投資者可能會因支付過高的股價而受到損失。</p>
<p>想知道分析師如何看待優信的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
<h2>收入增長指標告訴我們關於高市銷率的什麼？</h2>
<p>為了證明其市銷率的合理性，優信需要實現超過行業的顯著增長。</p>
<p>如果我們回顧過去一年的收入增長，該公司實現了 73% 的驚人增長。與三年前相比，收入總共也增長了 25%，這主要得益於過去 12 個月的增長。因此，我們可以首先確認該公司在這段時間內確實做得很好。</p>
<p>展望未來，根據跟蹤該公司的兩位分析師的預測，預計收入將在未來三年內每年增長 88%。與此同時，行業其他公司的年均增長率僅為 7.7%，顯然吸引力較低。</p>
<p>考慮到這一點，優信的市銷率高於大多數其他公司是可以理解的。顯然，股東們不願意拋售可能瞄準更繁榮未來的股票。</p>
<h2>最終結論</h2>
<p>優信股票的大幅反彈使公司的市銷率大幅提升。有人認為，在某些行業中，市銷率是一個較差的價值衡量標準，但它可以是一個強有力的商業情緒指標。</p>
<p>正如我們所懷疑的，我們對優信分析師預測的審查顯示，其優越的收入前景正在推動其高市銷率。在這一階段，投資者認為收入惡化的潛力相當小，從而證明了這一高市銷率的合理性。除非分析師們真的失誤，否則這些強勁的收入預測應該會保持股價的穩定。</p>
<p>話雖如此，請注意 <strong>優信在我們的投資分析中顯示出 3 個警告信號</strong>，其中 2 個信號有些不太令人愉快。</p>
<p>如果這些 <strong>風險讓你重新考慮對優信的看法</strong>，請瀏覽我們的高質量股票互動列表，以瞭解還有什麼其他選擇。</p>
<p>移動基礎設施用於國防和災難</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

優信

<p>優信有限公司 (NASDAQ:UXIN) 的股價最近上漲了 29%，儘管過去一年仍下跌了 25%。該公司的市銷率 (P/S) 為 1.8 倍，高於許多專業零售行業的公司，這引發了對其估值的質疑。優信在過去一年中顯示出 73% 的顯著收入增長，預計在未來三年將以 88% 的年增長率增長，超過行業平均水平的 7.7%。儘管前景樂觀，但投資者應謹慎，因為投資分析中存在三個警示信號</p>

<p><strong>Uxin Limited</strong> (NASDAQ:UXIN) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 25% in the last twelve months.</p>
<div class="lb-trans"><p><strong>優信有限公司</strong> (NASDAQ:UXIN) 的股票在經歷了一段動盪期後，最近一個月表現非常出色，漲幅達到 29%。並不是所有股東都會感到歡欣鼓舞，因為過去十二個月股價仍然下跌了令人失望的 25%。</p>
</div><p>After such a large jump in price, when almost half of the companies in the United States' Specialty Retail industry have price-to-sales ratios (or &#34;P/S&#34;) below 0.5x, you may consider Uxin as a stock probably not worth researching with its 1.8x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>在經歷如此大幅的價格跳升後，考慮到美國特種零售行業中幾乎一半的公司市銷率（&#34;P/S&#34;）低於 0.5 倍，你可能會認為優信的 1.8 倍市銷率並不值得研究。然而，市銷率可能因某種原因而偏高，需要進一步調查以確定其合理性。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>See our latest analysis for Uxin</p>
<div class="lb-trans"><p>查看我們對優信的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974" alt="" original-src="https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974"/></p>
<p>NasdaqGS:UXIN Price to Sales Ratio vs Industry December 31st 2025</p>
<div class="lb-trans"><p>NasdaqGS:UXIN 市銷率與行業比較 2025 年 12 月 31 日</p>
</div><h3>What Does Uxin's P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>優信的市銷率對股東意味着什麼？</h3>
</div><p>Uxin certainly has been doing a good job lately as it's been growing revenue more than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>優信最近的表現確實不錯，其收入增長超過了大多數其他公司。似乎許多人預計強勁的收入表現將持續，這提高了市銷率。然而，如果情況並非如此，投資者可能會因支付過高的股價而受到損失。</p>
</div><p>Keen to find out how analysts think Uxin's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析師如何看待優信的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The High P/S?</h2>
<div class="lb-trans"><h2>收入增長指標告訴我們關於高市銷率的什麼？</h2>
</div><p>In order to justify its P/S ratio, Uxin would need to produce impressive growth in excess of the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，優信需要實現超過行業的顯著增長。</p>
</div><p>If we review the last year of revenue growth, the company posted a terrific increase of 73%. Revenue has also lifted 25% in aggregate from three years ago, mostly thanks to the last 12 months of growth. So we can start by confirming that the company has actually done a good job of growing revenue over that time.</p>
<div class="lb-trans"><p>如果我們回顧過去一年的收入增長，該公司實現了 73% 的驚人增長。與三年前相比，收入總共也增長了 25%，這主要得益於過去 12 個月的增長。因此，我們可以首先確認該公司在這段時間內確實做得很好。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 88% per year during the coming three years according to the two analysts following the company. Meanwhile, the rest of the industry is forecast to only expand by 7.7% per year, which is noticeably less attractive.</p>
<div class="lb-trans"><p>展望未來，根據跟蹤該公司的兩位分析師的預測，預計收入將在未來三年內每年增長 88%。與此同時，行業其他公司的年均增長率僅為 7.7%，顯然吸引力較低。</p>
</div><p>In light of this, it's understandable that Uxin's P/S sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.</p>
<div class="lb-trans"><p>考慮到這一點，優信的市銷率高於大多數其他公司是可以理解的。顯然，股東們不願意拋售可能瞄準更繁榮未來的股票。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最終結論</h2>
</div><p>The large bounce in Uxin's shares has lifted the company's P/S handsomely. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.</p>
<div class="lb-trans"><p>優信股票的大幅反彈使公司的市銷率大幅提升。有人認為，在某些行業中，市銷率是一個較差的價值衡量標準，但它可以是一個強有力的商業情緒指標。</p>
</div><p>As we suspected, our examination of Uxin's analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.</p>
<div class="lb-trans"><p>正如我們所懷疑的，我們對優信分析師預測的審查顯示，其優越的收入前景正在推動其高市銷率。在這一階段，投資者認為收入惡化的潛力相當小，從而證明了這一高市銷率的合理性。除非分析師們真的失誤，否則這些強勁的收入預測應該會保持股價的穩定。</p>
</div><p>Having said that, be aware <strong>Uxin is showing 3 warning signs</strong> in our investment analysis, and 2 of those are a bit unpleasant.</p>
<div class="lb-trans"><p>話雖如此，請注意 <strong>優信在我們的投資分析中顯示出 3 個警告信號</strong>，其中 2 個信號有些不太令人愉快。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Uxin</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對優信的看法</strong>，請瀏覽我們的高質量股票互動列表，以瞭解還有什麼其他選擇。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災難</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

優信有限公司（納斯達克股票代碼：UXIN）股價上漲 29%，看起來正合適